ELI LILLY & CO (LLY)

Don’t Miss Out! 3 Top-Tier Blue-Chip Growth Stocks for Your Must-Buy List

These three large-cap blue-chip growth stocks are certainly worth considering as core portfolio holdings in this current environment.

Which Companies Will Join the Trillion-Dollar Team in 2024? Our 3 Best Guesses

Explore the dynamics of money-maker stocks in 2024, which are fueled by AI advancements and robust economic growth.

Meet Eli Lilly's Secret Weapon in the Billion-Dollar Weight-Loss Drug Market

Lilly recently announced news that could solve a big problem.

3 Speculative Weight Loss Drug Stocks to Bet On for Big Gains

These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.

Missed Out on Novo Nordisk? 2 Healthcare Stocks With Big Catalysts on the Horizon.

Good news could be just around the corner for two drugmakers not named Novo Nordisk.

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Better Buy: Pfizer vs. Viking Therapeutics

These two pharma stocks have followed distinct paths of late. Which is the better investment?

3 Stocks With the Potential to Surpass Analyst Expectations for 2024

These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.

Eli Lilly (LLY) Advances But Underperforms Market: Key Facts

Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.

7 High-Flying Stocks That Are Majorly Overdue for a Pullback

After performing strongly since the start of the year, it's time to sell these stocks due for a pullback before they reverse course.

TikTok’s Crackdown on Ozempic Influencers Threatens Weight-Loss Drug Hype Machine

Creators say the rules are unfair and harmful to their businesses

6 Stocks Positioned to Soar as Investors Focus on MASH

Investors are making a lot of money on obesity plays. Obesity is at epidemic proportions, so it's easy to see why obesity drugs including GLP-1 agonists have exploded in the marketplace. This class of drugs was originally designed to manage blood sugar levels in diabetics but was expanded to treat obesity, an even bigger market. JP Morgan analyst Richard Vosser estimated the global obesity drug market will reach $71 billion by 2032.

Africa’s Biggest Drugmaker Can Help Ease Obesity Medicine Supply Crunch

Africa’s biggest drugmaker could potentially help ease a growing supply crunch for the world’s hottest obesity medications.

Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential

Altimmune has a modest market cap but an incredibly promising GLP-1 drug.

Most people on weight loss drugs are spending less on restaurants and takeout, survey says

The findings add to concerns that GLP-1s could take a bite out of the bottom lines of some of the biggest restaurant companies and packaged food makers.

3 Relatively Safe Growth Stocks You Can Buy and Hold

Low risk and high-reward potential? These stocks could offer both.

3 Relatively Safe Growth Stocks You Can Buy and Hold

Low risk and high-reward potential? These stocks could offer both.

Stock Market Sells Off; Taiwan Semi, ASML, Netflix, Tesla In Focus: Weekly Review

The Nasdaq and S&P 500 tumbled below their 50-day lines.

Strong Buy Alert: 7 No-Brainer Stocks to Scoop Up Now

Investors should not ignore these highly rated stocks to buy now because they deserve their reputation as the market heats up.

Noteworthy Thursday Option Activity: RILY, LLY, GLNG

How The Weight-Loss Bonanza Prompted A ResMed Sell-Off — But Could Soon Drive Shares Higher

ResMed stock reversed higher Thursday after an analyst suggested weight-loss drugs could drive CPAP use.

Want to Double Your Tax Refund in 2024? 7 Stocks to Buy Now.

Investors wondering which tax refund stocks to invest in should consider these names, each of which is a capital compounder.

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

Eli Lilly subsidiary ends lucrative collaboration with Durham biotech

Which S&P500 stocks are moving on Tuesday?

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.